Neuren Pharmaceuticals

Últimas notícias

Manchetes no idioma original da fonte.

• Neuren Pharmaceuticals Limited (ASX:NEU): First Dividend Arrives as Phase 3 Investment Accelerates (abre em uma nova aba)

  Kalkine · 1 de out. de 2026

• What Will Its First European Launch Mean for Neuren (ASX:NEU)? (abre em uma nova aba)

  Kalkine Media · 30 de set. de 2026

• Neuren Pharmaceuticals (ASX:NEU): How Could the New Trofinetide Patent Extend Protection? (abre em uma nova aba)

  Kalkine · 29 de set. de 2026

• Neuren Pharmaceuticals (ASX:NEU): US Patent Allowance Supports Potential Trofinetide Protection Extension (abre em uma nova aba)

  Kalkine · 29 de set. de 2026

• What lies ahead for Neuren (ASX:NEU) as FDA talks draw near? (abre em uma nova aba)

  Kalkine Media · 28 de set. de 2026

• Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best? (abre em uma nova aba)

  The Motley Fool Australia · 21 de set. de 2026

• What Could Neuren Pharmaceuticals (ASX:NEU) Mean for Midcaps? (abre em uma nova aba)

  Kalkine Media · 17 de set. de 2026

• Sigma Healthcare, Neuren and Mesoblast: Financial Performance Across ASX Healthcare (abre em uma nova aba)

  Kalkine · 14 de set. de 2026

• ASX Healthcare Stocks to Watch in September 2026: Sigma Healthcare (ASX:SIG), Neuren Pharmaceuticals (ASX:NEU) and Mesoblast (ASX:MSB) (abre em uma nova aba)

  Kalkine · 14 de set. de 2026

• Neuren Pharmaceuticals (ASX:NEU): DAYBUE Royalties and NNZ-2591 Pipeline Define the Growth Story (abre em uma nova aba)

  Kalkine · 7 de set. de 2026

• Neuren Pharmaceuticals (ASX:NEU) Up 1.51% — Royalties and NNZ-2591 Pipeline in the Spotlight (abre em uma nova aba)

  Kalkine · 4 de set. de 2026